Tesamorelin

Tesamorelin is a synthetic GHRH analog consisting of the full 44-amino-acid human GHRH(1-44) sequence with a trans-3-hexenoic acid modification at the N-terminus. This modification protects the molecule from DPP-4 cleavage while preserving the complete biological activity of native GHRH. Tesamorelin is notable as the only GHRH analog to have undergone full FDA-approved clinical trials — it was studied and approved for the reduction of excess abdominal fat in HIV-associated lipodystrophy, giving it the most rigorous clinical dataset of any GH-releasing peptide.

Tesamorelin activates the GHRH receptor on pituitary somatotrophs with full agonist potency. Its mechanism is functionally identical to CJC-1295 No DAC — cAMP-mediated GH vesicle release — but Tesamorelin retains the complete 44-amino-acid sequence of native GHRH rather than the truncated 29-amino-acid fragment. This full-length structure may provide additional receptor binding affinity and more complete activation of downstream signaling. Clinical studies demonstrated that tesamorelin increases GH secretion by approximately 2-5 fold and elevates IGF-1 levels by 40-80% from baseline, with peak GH responses occurring 15-30 minutes post-injection.

The clinical research on tesamorelin stands out for its focus on visceral adipose tissue (VAT) — the metabolically active fat depot surrounding abdominal organs that is associated with cardiovascular risk, insulin resistance, and metabolic syndrome. Pivotal trials showed a mean 15-18% reduction in trunk fat over 26 weeks, with proportionally greater reduction in visceral versus subcutaneous fat. Concurrent improvements in triglycerides, cholesterol ratios, and inflammatory biomarkers (C-reactive protein) were documented. Importantly, tesamorelin did not worsen glucose homeostasis — a concern with exogenous HGH — and demonstrated an acceptable long-term safety profile across 52-week extension studies.

Tesamorelin is best suited for researchers investigating visceral fat reduction, metabolic syndrome management, body composition optimization, and age-related GH decline. Its clinical pedigree makes it particularly appropriate for researchers who prioritize compounds with extensive human safety data. It can be used alone or stacked with Ipamorelin for synergistic GHRH/GHRP activation.

Reconstitute with 2.5ml bacteriostatic water (yielding 2mg/ml). Administer via subcutaneous injection into abdominal tissue, typically 1-2mg per day. The clinical dosing used in FDA trials was 2mg daily via subcutaneous injection. Tesamorelin has a half-life of approximately 26-38 minutes, supporting once-daily dosing timed before sleep or upon waking. Store reconstituted solution at 2-8C and use within 28 days. Lyophilized powder should be refrigerated.